pemigatinib
Selected indexed studies
- Pemigatinib. (, 2006) [PMID:37094059]
- Pemigatinib. (, 2012) [PMID:36592395]
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. (Lancet Oncol, 2020) [PMID:32203698]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pemigatinib. (2006) pubmed
- Pemigatinib. (2012) pubmed
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. (2020) pubmed
- Pemigatinib: First Approval. (2020) pubmed
- Pemigatinib: A Review in Advanced Cholangiocarcinoma. (2024) pubmed
- Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. (2022) pubmed
- Pemigatinib for cholangiocarcinoma. (2022) pubmed
- An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. (2024) pubmed
- PMID:38232190 (2022) pubmed
- Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. (2024) pubmed